The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth? - PubMed

Review

The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth?

S Olver et al. Tissue Antigens. 2007 Apr.

Abstract

Successful tumour immunity relies on innate and adaptive immune responses, with cytokines like interleukin 4 (IL-4) known to influence tumour clearance in both positive and negative ways. Here, we summarise some of the murine tumour models used over the past two decades to assess the impact of IL-4 on tumour immunity, with emphasis on the effects of IL-4 on the tumour-induced CD8 T-cell response. These data are compared with our own recent studies showing that IL-4 impairs CD8+ T-cell-mediated immunity against the mastocytoma cell line P815 expressing the immunogenic HLA-CW3 gene; moreover, we hypothesise that quantitative and qualitative differences in the HLA-CW3-induced CD8+ T-cell response impair control of tumour growth and aid the development of secondary tumours. We conclude that the duplicitous effects of IL-4 on tumour immunity depend on the type of effector cell (adaptive/innate) mediating tumour clearance and whether tumour growth depends on stromal infrastructure. Thus, the search for factors that improve or weaken the effectiveness of tumour-specific T cells has to be continued to improve modern approaches of immunotherapy against cancer.

Similar articles

• Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.

  Olver S, Groves P, Buttigieg K, Morris ES, Janas ML, Kelso A, Kienzle N. Olver S, et al. Cancer Res. 2006 Jan 1;66(1):571-80. doi: 10.1158/0008-5472.CAN-05-1362. Cancer Res. 2006. PMID: 16397274

• Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.

  Balkow S, Loser K, Krummen M, Higuchi T, Rothoeft T, Apelt J, Tuettenberg A, Weishaupt C, Beissert S, Grabbe S. Balkow S, et al. Exp Dermatol. 2009 Jan;18(1):78-87. doi: 10.1111/j.1600-0625.2008.00800.x. Epub 2008 Oct 22. Exp Dermatol. 2009. PMID: 19054060

• IL-23 promotes tumour incidence and growth.

  Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M. Langowski JL, et al. Nature. 2006 Jul 27;442(7101):461-5. doi: 10.1038/nature04808. Epub 2006 May 10. Nature. 2006. PMID: 16688182

• Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?

  Perret R, Ronchese F. Perret R, et al. Tissue Antigens. 2008 Sep;72(3):187-94. doi: 10.1111/j.1399-0039.2008.01088.x. Epub 2008 Jul 9. Tissue Antigens. 2008. PMID: 18627571 Review.

• TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.

  Conroy H, Marshall NA, Mills KH. Conroy H, et al. Oncogene. 2008 Jan 7;27(2):168-80. doi: 10.1038/sj.onc.1210910. Oncogene. 2008. PMID: 18176598 Review.

Cited by

• Significant association of the cytokine variants with head and neck cancer risk: evidence from meta-analysis.

  Xiao TT, Li X, Xu Y, Li Y. Xiao TT, et al. Eur Arch Otorhinolaryngol. 2018 Feb;275(2):483-496. doi: 10.1007/s00405-017-4820-4. Epub 2017 Nov 28. Eur Arch Otorhinolaryngol. 2018. PMID: 29185028

• IL-4 in the brain: a cytokine to remember.

  Gadani SP, Cronk JC, Norris GT, Kipnis J. Gadani SP, et al. J Immunol. 2012 Nov 1;189(9):4213-9. doi: 10.4049/jimmunol.1202246. J Immunol. 2012. PMID: 23087426 Free PMC article. Review.

• Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.

  Negi AK, Renuka, Bhatnagar A, Agnihotri N. Negi AK, et al. Inflammopharmacology. 2016 Feb;24(1):11-22. doi: 10.1007/s10787-015-0259-7. Epub 2016 Jan 9. Inflammopharmacology. 2016. PMID: 26749133

• Interleukin 4 and cancer resistance in glioblastoma multiforme.

  Detchou D, Barrie U. Detchou D, et al. Neurosurg Rev. 2024 Aug 21;47(1):448. doi: 10.1007/s10143-024-02695-4. Neurosurg Rev. 2024. PMID: 39164434 Review.

• Lymphocytes in cancer development: polarization towards pro-tumor immunity.

  Ruffell B, DeNardo DG, Affara NI, Coussens LM. Ruffell B, et al. Cytokine Growth Factor Rev. 2010 Feb;21(1):3-10. doi: 10.1016/j.cytogfr.2009.11.002. Epub 2009 Dec 11. Cytokine Growth Factor Rev. 2010. PMID: 20005150 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal